

Note on COVID-19 measures at LEUKOCARE

Dear all,

With regard to the current situation concerning COVID-19, we want to inform our customers and potential clients that we reacted promptly already weeks ago and implemented preventive measures to minimize the impact of COVID-19related disruptions on our business and running projects. We are actively monitoring the COVID-19 situation and adapt our lean organization continuously to make sure development timelines are being met and project milestones are delivered on time.

As of today, no cases of COVID-19 are known within LEUKOCARE. We are currently running our operations without neither major disruptions nor any threats to business continuity and client delivery, and are striving to continue to do so.

We have created a COVID-19 Task Force for the active and continuous real-time assessment of the situation and to drive comprehensive company-wide measures. To assure health and reduce infection risk for our employees, and to ensure business continuity, we have tightened our strict hygiene protocol, enabled maximum home office work and rolled out web-based communication tools and additional IT equipment for our employees, among other measures.

Moreover, to reduce contact to a minimum, we have separated our company personnel in two distinct groups, which now communicate and coordinate projects very closely, but are completely separated from each other operationally in the labs to enable continuation of business with at least one group in case there are COVID-19 cases in the other group. We keep monitoring our supply chain and have stocked required materials as precautionary measures.

These proactive measures reflect our strong commitment to ensuring ongoing and future business operations, while always also caring for the health of our team. We will do everything possible within our sphere of influence to avoid impact on project timelines.

We will keep you informed on all relevant developments. Please do not hesitate to reach out to us if you have any questions.

Yours sincerely

Michael Scholl CEO LEUKOCARE

Dr. Andreas Seidl COO LEUKOCARE